GO41944/ StarGlo
- Status: nicht rekrutierend, NCT04408638
- A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Kurzinformation
- Ansprechpartner:
Prof. Dr. Gerald Illerhaus (Leiter der Klinischen Prüfung)
Telefon: 0711 278-30401
E-Mail: g.illerhaus@klinikum-stuttgart.de - Studienzentrale
Telefon: 0711 278-30410, -30411, -30414
E-Mail: scc-studienzentrale@klinikum-stuttgart.de
Pola-R-ICE
- Status: aktiv, NCT04833114
- An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with diffuse large B-cell lymphoma (DLBCL) at first progression or relapse
- Kurzinformation
- Ansprechpartner:
Prof. Dr. Gerald Illerhaus
Telefon: 0711 278-30401
E-Mail: g.illerhaus@klinikum-stuttgart.de - Studienzentrale
Telefon: 0711 278-30410, -30411, -30414
E-Mail: scc-studienzentrale@klinikum-stuttgart.de